Chen et al. [19] and Zgarbová and Vrzal [23] demonstrated that AhR antagonists like carbidopa and natural AhR agonists, respectively, can effectively reduce AR activity and prostate cancer cell viability, highlighting the potential for these compounds in therapeutic applications. This evidence concerns the gene AHR and prostate cancer.